Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Orvepitant - NeRRe therapeutics

Drug Profile

Orvepitant - NeRRe therapeutics

Alternative Names: 823296; GW 823296; GW823296X

Latest Information Update: 20 May 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Developer NeRRe Therapeutics
  • Class Amides; Antidepressants; Antipruritics; Antitussives; Anxiolytics; Piperidines; Pyrazines; Pyrroles
  • Mechanism of Action Neurokinin 1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Cough; Pruritus
  • Discontinued Anxiety disorders; Major depressive disorder; Post-traumatic stress disorders

Most Recent Events

  • 31 Jan 2020 Orvepitant is still in phase II trials for Cough in USA
  • 27 Aug 2019 Efficacy and adverse events data from the phase II VOLCANO-2 trial in Cough released by NeRRe Therapeutics
  • 27 Aug 2019 NeRRe Therapeutics plans a phase III trial in Cough (PO) (after completion of VOLCANO-2 trial)
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top